Select a medication above to begin.
Vafseo
vadadustat
Black Box Warnings .
Risk of Death, Myocardial Infarction, Stroke, Venous Thromboembolism, and Thrombosis of Vascular Access Increased
risk of thrombotic vascular events, including major adverse cardiovascular events (MACE) increased; targeting Hgb level >11 g/dL further incr. risk of death, arterial venous thrombotic events, as with ESAs; no trial has identified Hgb target level, tx dose, or dosing strategy that does not incr. these risks; use lowest dose sufficient to decr. RBC transfusion need
Adult Dosing .
Dosage forms: TAB: 150 mg, 300 mg, 450 mg
anemia, CKD-associated
- [individualize dose PO qd]
- Start: 300 mg PO qd; Max: 600 mg/day; Info: for patients on dialysis >3mo; use lowest dose to maintain Hgb level sufficient to reduce RBC transfusion need; may incr. dose by 150 mg no more frequently than q4wk to maintain Hgb 10-11 g/dL; decr. dose if Hgb incr. >1 g/dL/2wk or >2 g/dL/4wk; if Hgb >11 g/dL, hold until Hgb <11 g/dL and decr. dose by 150 mg; may give RBC transfusion or ESA rescue tx if Hgb <9 g/dL or inadequate Hgb response; hold tx if ESA given, may resume when Hgb >10 g/dL; see pkg insert for detailed restart criteria; do not continue beyond 24wk if inadequate response; give iron supplement if serum ferritin level <100 mcg/L, or if serum transferrin saturation <20%; do not cut/crush/chew tab
renal dosing
- [see below]
- renal impairment: not defined
- HD/PD: no adjustment; no supplement
hepatic dosing
- [see below]
- Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined; acute hepatic disease/cirrhosis: avoid use
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.